GTS Securities’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-17,806
Closed -$145K 1995
2024
Q3
$145K Buy
17,806
+16,488
+1,251% +$165K ﹤0.01% 3734
2024
Q2
$17.6K Sell
1,318
-192
-13% -$5.73K ﹤0.01% 3798
2024
Q1
$70.1K Sell
1,510
-1,663
-52% -$86.1K ﹤0.01% 3586
2023
Q4
$214K Sell
3,173
-115
-3% -$7.04K ﹤0.01% 3506
2023
Q3
$238K Buy
+3,288
New +$263K ﹤0.01% 3266

Other funds holding DNA

GTS Securities's DNA Position: Q3 2024 in Review

GTS Securities sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 6,086 shares — an estimated $61K sold.

GTS Securities first reported a position in DNA in Q2 2023 and held it in 5 quarters. The position peaked at $419K in Q2 2023. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • GTS Securities reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • GTS Securities sold 6,086 Ginkgo Bioworks shares in Q3 2024, an estimated $61K.
  • GTS Securities first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 5 quarters.
  • GTS Securities's Ginkgo Bioworks position peaked at $419K in Q2 2023.
  • 158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.